Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
14 studies found for:    weill | Open Studies | "Colonic Diseases"
Show Display Options
Rank Status Study
1 Recruiting Endoscopic Resection Multicenter Registry
Conditions: Gastrointestinal Neoplasms;   Gastrointestinal Disease;   Gastric Cancer;   Gastric Neoplasm;   Gastric Polyp;   Esophageal Neoplasms;   Duodenal Neoplasms;   Duodenal Polyp;   Stomach Neoplasm;   Stomach Polyp;   Neoplasms;   Colon Polyp;   Colon Neoplasm
Intervention: Procedure: Endoscopic Resection
2 Recruiting Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders
Conditions: Ampullary Cancer;   Duodenal Cancer;   Bile Duct Cancer;   Bile Duct Disorders;   Gallstones;   Obstructive Jaundice;   Pancreatic Disorders (Noncancerous);   Colorectal Cancer;   Esophageal Cancer;   Barrett's Esophagus;   Gastric Malignancies;   Pancreatic Cancer;   Pediatric Gastroenterology;   Cholangiocarcinoma;   Pancreatic Pseudocysts;   Acute and Chronic Pancreatitis;   Recurrent Pancreatitis;   Cholangitis;   Bile Leak;   Biliary Strictures;   Pancreatic Divisum;   Biliary and Pancreatic Stones;   Choledocholithiasis
Intervention: Procedure: Interventional Endoscopy
3 Recruiting 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Conditions: Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention: Drug: 177Lu-J591
4 Recruiting A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Conditions: Colitis, Ulcerative;   Inflammatory Bowel Diseases
Interventions: Drug: Placebo IV;   Drug: Placebo SC;   Drug: Ustekinumab IV;   Drug: Ustekinumab SC
5 Recruiting A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Conditions: Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis;   Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab;   Drug: No Biologics
6 Recruiting Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Condition: Lynch Syndrome
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Naproxen;   Other: Placebo
7 Recruiting Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
Condition: Colitis, Ulcerative
Intervention: Drug: PF-06480605
8 Recruiting A Study of LY3074828 in Participants With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: LY3074828;   Drug: Placebo
9 Recruiting A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors
Condition: Ulcerative Colitis
Interventions: Drug: Etrozulimab;   Drug: Placebo
10 Recruiting PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
11 Recruiting A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Condition: Colitis, Ulcerative
Interventions: Drug: Etrolizumab;   Drug: Placebo
12 Recruiting Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
Condition: Ulcerative Colitis
Intervention: Drug: Etrolizumab
13 Recruiting A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Condition: Ulcerative Colitis
Intervention:
14 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132

Study has passed its completion date and status has not been verified in more than two years.